Arcus Biosciences Inc
RCUS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.6B
Close$
$-25.05
187.5% downside
Current Fair Value
187.5% downsideOvervalued by 187.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.60 Billion |
|---|---|
| Enterprise Value | $3.58 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.29 |
| Beta | 0.8 |
| Outstanding Shares | 126,100,000 |
Return
| Return on Equity | -97.41% |
|---|---|
| Return on Assets | -48.92% |
| Return on Invested Capital | -60.61% |
Valuation & Multiples
| P/E Ratio | -7.28 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 9.54 |
| Enterprise Value to Revenue | 30.62 |
| Enterprise Value to EBIT | -8.14 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$21.98 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$-0.90
Average shareholder expectationRevenue Estimate
$12.61 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 46.12% |
|---|---|
| Total Calls | 316▼ 99.91% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 46.96%▼ 63.91% |
|---|---|
| Total Invested | $1.82B▼ 29.42% |
| Investors Holding | 72▼ 149.00% |
ESG Score
No data